Panolos Bioscience, a biopharmaceutical company focused on the development of multi-specific therapeutics to treat cancer, auto-immune diseases and rare diseases, has entered into a collaboration with Chime Biologics, a CDMO, for a novel multi-specific protein drug, PB203, for solid tumors (PDAC/ICC), which is in the preclinical stage with plans to conduct a Phase I trial in the U.S. Chime Biologics will provide CMC services for the development and manufacture of PB203 from cell line developm...